Form D · Biotechnology
Adaptive Biotechnologies Corp
Seattle, WA · CIK 0001478320
Offering snapshot reported May 11, 2015 · SEC filing
- Reported sold
- $195M Offering amount: $195M
- Investors reported
- 16 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 5, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 11, 2015 | Initial | $195,099,954 | No comparison | 16 | SEC filing |
| Jan 22, 2015 | Initial | $93,750,000 | No comparison | 4 | SEC filing |
| Jan 21, 2015 | Initial | $95,716,444 | No comparison | 61 | SEC filing |
| Aug 4, 2014 | Amendment | $106,999,480 | $2,000,000vs Apr 15, 2014 | 6 | SEC filing |
| Apr 15, 2014 | Initial | $104,999,480 | No comparison | 4 | SEC filing |
| Jul 12, 2013 | Initial | $5,024,792 | No comparison | 3 | SEC filing |
| Jun 21, 2012 | Initial | $2,649,272 | No comparison | 37 | SEC filing |
| Jun 2, 2011 | Initial | $5,821,524 | No comparison | 63 | SEC filing |
| Dec 28, 2009 | Initial | $3,955,000 | No comparison | 50 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-239593
Source: Form D, filed May 11, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Chris Carlson | Executive |
| Chad Cohen | Director |
| Kathleen Determann | Executive |
| Rob Hershberg | Director |
| Lee Huntsman | Director |
| Arnold Levine | Director |
| Peter Neupert | Director |
| Harlan Robins | Executive |
| Chad Robins | Director, Executive |
| Rob Rosen | Director |
| Dean Schorno | Executive |
| John Stuelpnagel | Director |
| Craig Weissman | Director |
| Tom Willis | Director |
| Andy Zoltners | Director |
| Andris Zoltners | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1551 Eastlake Avenue East Suite 200
Seattle, WA, 98102
Seattle, WA, 98102